Organisation › Details

Santhera Pharmaceuticals Holding AG (SIX: SANN)

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of severe neuromuscular and neurodegenerative diseases, an area of high unmet medical need which includes many orphan and niche indications with no current therapy. Santhera's first product, Catena® to treat Friedreich's Ataxia is marketed in Canada. *

 

Period Start 2004-09-08 merged
  Group Santhera (Group)
  Predecessor Graffinity Pharmaceuticals AG
Product Industry BIOTECH
Person Person Meier, Thomas (Santhera 201303 CEO before CSO)
     
Region Region Liestal BL
  Country Switzerland
  Street 49 Hammerstr.
  City 4410 Liestal BL
  Tel +41-61-906-8950
    Address record changed: 2012-01-24
     
Basic data Employees D: 101 to 500 (2017-12-31)
  Currency CHF
  Annual sales 22,943,000 (sales, net, consolidated (2017) 2017-12-31)
  Profit -51,532,000 (2017-12-31)
  Cash 45,195,000 (2017-12-31)
     
    * Document for �About Section�: Santhera Pharmaceuticals. (7/27/11). "Press Release: Publication in BRAIN Highlights Medical Potential of Santhera’s Catena in Leber’s Hereditary Optic Neuropathy". Liestal.
     
   
Record changed: 2019-06-09

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 650x99px

More documents for Santhera (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] – Putting Information into Context 600x60px




» top